For more insights on the market share of various regions - Download a free sample now!
Company Profiles
The proton pump inhibitors (PPIs) market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. The proton pump inhibitors (PPIs) market report provides complete insights on key vendors including AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Johnson and Johnson Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Few companies with Key offerings -
- Dr. Reddys Laboratories Ltd. - The company offers Omeprazole which is a specific inhibitor of the acid pump in the parietal cell.
- Eisai Co. Ltd. - The company offers proton pump inhibitor Pariet tablets that are used as a treatment for gastric ulcer duodenal ulcer reflux esophagitis and other gastroenterological diseases.
- Johnson and Johnson Inc. - The company offers a wide range of proton pump inhibitors.
- Pfizer Inc., - The company offers Nexium 24HR which is a proton pump inhibitor, which means it stops acid production at the source, by blocking the pumps that release acid into the stomach.
- Takeda Pharmaceutical Co. Ltd.. - The company offers DEXILANT which is a proton pump inhibitor with a Dual Delayed Release formulation designed to provide two separate releases of medication.
- To know about all major vendors with their key offerings - Click Now!
Market Dynamics
The market is driven by factors such as the reformulation of drugs, growth in prescription rate, and the strong prevalence of gastroesophageal reflux disease. However, the increasing lawsuits against PPIs are hindering market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge. The proton pump inhibitors (PPIs) market analysis report also provides detailed information on other upcoming trends that will have a far-reaching effect on the market growth.
Competitive Analysis
The competitive scenario provided in the proton pump inhibitors (PPIs) market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
Market Segmentation
- By Product, the market is classified into OTC PPIs and prescription PPIs. The proton pump inhibitors (PPIs) market share growth by the OTC PPIs segment will be significant during the forecast period.
- By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market.
Related Reports -
Stroke Therapeutics Market -The stroke therapeutics market share is expected to increase by USD 1.54 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5.00%. Download a free sample now!
Sickle Cell Disease Treatment Market -The sickle cell disease treatment market share is expected to increase by USD 2.33 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 11.36%. Download a free sample now!
Proton Pump Inhibitors (PPIs) Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.17% |
Market growth 2021-2025 |
USD 3.45 billion |
Market structure |
Fragmented |
YoY growth (%) |
3.67 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 35% |
Key consumer countries |
US, China, Germany, Canada, and UK |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Johnson and Johnson Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article